AZD2171 cancer drug molecule

AZD2171 cancer drug molecule

A624/0511 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 37.9MB

Downloadable file size: 481.4KB

Price image Pricing

Please login to use the price calculator


Credit: DR TIM EVANS/SCIENCE PHOTO LIBRARY

Caption: AZD2171 cancer drug. Computer model of a molecule of the cancer drug AZD2171. This drug (trade name Recentin) is being developed by AstraZeneca. As of 2007 it is undergoing clinical trials for treatment of non-small cell lung cancer and colorectal cancer in adults, as well as tumours of the central nervous system in children. It belongs to a class of drugs known as tyrosine kinase inhibitors. These drugs bind to tyrosine kinase growth factor receptors on the cancer cell's surface, inactivating them and so stopping cell growth and proliferation. Atoms are colour-coded: carbon (yellow), hydrogen (white), nitrogen (blue), fluorine (green) and oxygen (red).

Release details: Model release not required. Property release not required.

Keywords: 2007, 21st century, agent, anti-cancer, artwork, astrazeneca, atom, atoms, azd2171, biochemical, biochemistry, biological, biology, brain, central nervous system, chemical, chemistry, chemotherapy, cns, colorectal, compound, compounds, drug, illustration, lung cancer, medical, medication, medicine, molecular, molecular model, molecule, molecules, non-small cell, oncological, oncology, one, pharmaceutical, pharmaceutics, pharmacological, pharmacology, recentin, single, space fill, space-fill, spacefill, structure, treatment, tumour, tumours, tyrosine kinase inhibitor

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.